WallStSmart

Ligand Pharmaceuticals Incorporated (LGND)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ligand Pharmaceuticals Incorporated generates 39057% more annual revenue ($290.54M vs $742,000). LGND leads profitability with a 67.9% profit margin vs 0.0%. LGND earns a higher WallStSmart Score of 67/100 (B-).

LGND

Strong Buy

67

out of 100

Grade: B-

Growth: 9.3Profit: 7.5Value: 4.7Quality: 7.0
Piotroski: 4/9Altman Z: 2.79

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LGNDOvervalued (-7.0%)

Margin of Safety

-7.0%

Fair Value

$173.85

Current Price

$283.49

$109.64 premium

UndervaluedFair: $173.85Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LGND3 strengths · Avg: 10.0/10
Profit MarginProfitability
67.9%10/10

Keeps 68 of every $100 in revenue as profit

Revenue GrowthGrowth
33.7%10/10

Revenue surging 33.7% year-over-year

EPS GrowthGrowth
825.0%10/10

Earnings expanding 825.0% YoY

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

LGND3 concerns · Avg: 3.7/10
PEG RatioValuation
1.534/10

Expensive relative to growth rate

P/E RatioValuation
29.8x4/10

Moderate valuation

Debt/EquityHealth
1.173/10

Elevated debt levels

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
15.7x4/10

Trading at 15.7x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : LGND

The strongest argument for LGND centers on Profit Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 67.9% and operating margin at 13.5%. Revenue growth of 33.7% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : LGND

The primary concerns for LGND are PEG Ratio, P/E Ratio, Debt/Equity.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

LGND profiles as a growth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

LGND is growing revenue faster at 33.7% — sustainability is the question.

LGND generates stronger free cash flow (24M), providing more financial flexibility.

Bottom Line

LGND scores higher overall (67/100 vs 24/100), backed by strong 67.9% margins and 33.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ligand Pharmaceuticals Incorporated

HEALTHCARE · BIOTECHNOLOGY · USA

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?